Proceeds PurposesProceeds of the financing will support clinical development of ALD518 and ALD403. ALD518, a monoclonal antibody to the pro-inflammatory cytokine IL-6, is currently being investigated in ongoing Phase 2 clinical studies in cancer related indications, which were retained by the company in its partnership with Bristol-Myers Squibb in 2009.